Stage-associated differences in the serum N- and O-glycan profiles of patients with non-small cell lung cancer.

Abstract

BACKGROUND:

Lung cancer is the leading cause of cancer death in China and around the world. Early detection is key to improving the survival rate of non-small cell lung cancer (NSCLC). Alteration in glycosylation has been observed in cancers, and glycans can be a source for the development of new biomarkers for NSCLC.

METHODS:

In this glycan biomarker discovery study, we measured serum N- and O-glycan profiles in NSCLC patients with different stages and healthy controls by performing lectin microarray analysis. The alterations of serum glycopatterns were compared between NSCLC patients and controls, and the stage-related changes in serum glycosylation were evaluated.

RESULTS:

There were 18 lectins (e.g., AAL, Jacalin, GSL-I and DBA) to give significantly alterations of serum glycopatterns in lung adenocarcinoma compared with control group. Meanwhile, 16 lectins (e.g., Jacalin, HHL, and PHA-E+L) exhibited significantly alterations of serum glycopatterns in squamous cell carcinoma (SCC) compared with control group. Importantly, most of the lectins showing altered signals exhibited significantly increased or decreased NFIs in patients with early stage adenocarcinoma and SCC.

CONCLUSIONS:

The serum glycan profiles were significantly different between NSCLC and healthy control, and most of the glycosylation changes had occurred at early stage. Further evaluation is needed to examine the diagnostic value of the glycan markers identified in this study.

• Authors: Yiqian Liang, Peng Han, Ting Wang, Hui Ren, Lei Gao, Puyu Shi, Shuo Zhang, Aimin Yang, Zheng Li, Mingwei Chen
• Journal: Clinical proteomics (Clin Proteomics) Vol. 16 Pg. 20 ( 2019) ISSN: 1542-6416 [Print] England
• PMID: 31168300 (Publication Type: Journal Article)